MedTrace Logo

Memory Improvement With Docosahexaenoic Acid Study (MIDAS)

NCT00278135 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 485

Last updated 2014-05-19

No results posted yet for this study

Summary

The purpose of this study is to investigate the effect of docosahexaenoic acid (DHA, 22:6n-3) in improving cognitive functions in subjects with age-related cognitive decline. DHA is a long chain omega-3 fatty acid (LC-PUFA) that plays an important role in neural and visual development and cardiovascular health.

Conditions

  • Age-Related Cognitive Decline
  • Age-Related Memory Disorders

Interventions

DIETARY_SUPPLEMENT

DHA (nutritional supplement) or placebo

oral 900mg/day

Sponsors & Collaborators

  • DSM Nutritional Products, Inc.

    lead INDUSTRY

Principal Investigators

  • Karin Yurko-Mauro, PhD · DSM Nutritional Products, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2008-10-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00278135 on ClinicalTrials.gov